D
Sell
6/4/2020Upgraded
Capstone Therapeutics Corp. (CAPS) was upgraded to D- from E+ on 6/4/2020 due to an increase in the total return index and volatility index.
E
Sell
5/20/2020Downgrade
Capstone Therapeutics Corp. (CAPS) was downgraded to E+ from D- on 5/20/2020 due to a significant decline in the solvency index, growth index and total return index. Operating cash flow declined 163.21% from -$299 to -$787, the quick ratio declined from 1.49 to 0.37, and debt to equity increased from -1.25 to -0.97.
D
Sell
11/7/2018Downgrade
Capstone Therapeutics Corp. (CAPS) was downgraded to D- from D on 11/7/2018 due to a major decline in the efficiency index, growth index and volatility index. Net income declined 154.23% from $1.28M to -$693, earnings per share declined from $0.0235 to -$0.0127, and EBIT declined 147.24% from $1.34M to -$633.
D
Sell
8/15/2018Upgraded
Capstone Therapeutics Corp. (CAPS) was upgraded to D from D- on 8/15/2018 due to a major increase in the efficiency index, solvency index and valuation index. Debt to equity declined from -1.57 to -12.94, net income increased 317.72% from -$587 to $1.28M, and total capital increased 161.18% from $832 to $2.17M.
D
Sell
1/18/2017Upgraded
Capstone Therapeutics Corp. (CAPS) was upgraded to D- from E+ on 1/18/2017 due to an increase in the total return index and volatility index.
E
Sell
11/11/2016Downgrade
Capstone Therapeutics Corp. (CAPS) was downgraded to E+ from D- on 11/11/2016 due to a noticeable decline in the solvency index, valuation index and volatility index. Debt to equity increased from -4.33 to 4.39.
D
Sell
3/11/2016Downgrade
Capstone Therapeutics Corp. (CAPS) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and efficiency index. Total capital declined 23.84% from $1.78M to $1.36M.
